Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909014 | 0.75 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL4175398 | 0.75 | TTR (0.30) | — | |
| SCHEMBL21218762 | 0.72 | APEX1 (0.38) | CYP1A2 | |
| SCHEMBL29236284 | 0.72 | — | — | |
| SCHEMBL30536512 | 0.69 | ALDH1A1 (0.33) | — | |
| SCHEMBL31088765 | 0.68 | ALDH1A1 (0.40) | CYP1A2 | |
| SCHEMBL3735662 | 0.68 | NCEH1 (0.41) | CYP1A2 | |
| SCHEMBL7173958 | 0.68 | ALDH1A1 (0.40) | CYP1A2 | |
| SCHEMBL10738156 | 0.68 | CYP3A4 (0.50) | CYP1A2 | |
| SCHEMBL27871748 | 0.68 | ALDH1A1 (0.33) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CYP1A2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.